Literature DB >> 29715155

Acquired EGFR T790M Mutation After Relapse Following EGFR-TKI Therapy: A Population-based Multi-institutional Study.

Takayuki Kaburagi1, Moriyuki Kiyoshima1, Takeshi Nawa2, Hideo Ichimura2, Takefumi Saito3, Kenji Hayashihara3, Hideyasu Yamada4, Hiroaki Satoh5, Takeo Endo6, Yoshihisa Inage6, Kazuhito Saito7, Masaharu Inagaki7, Nobuyuki Hizawa8, Yukio Sato8, Hiroichi Ishikawa9, Mitsuaki Sakai9, Koichi Kamiyama10, Norihiro Kikuchi11, Hiroyuki Nakamura12, Kinya Furukawa12, Takahide Kodama13, Takaaki Yamashita14, Akihiro Nomura15, Susumu Yoshida15.   

Abstract

AIM: To describe the prevalence and determinants of acquired epidermal growth factor receptor (EGFR) T790M gene mutation in a clinical practice setting.
MATERIALS AND METHODS: We performed a retrospective chart review study between January 2013 and November 2017 across multiple institutes, covering a population of 3 million people.
RESULTS: We reviewed the charts of 233 patients non-small cell lung cancer with EGFR mutations. Of them, 99 (42.5%) patients had acquired T790M mutations in EGFR. Patients ≥75 years old and patients with an exon 19 deletion had higher rates of acquired T790M mutation than did younger patients and those with an exon 21 L858R mutation. In 75 patients treated with afatinib, 34 (45.3%) patients had acquired T790M mutation. The sensitivity of T790M mutation detection was lower in plasma specimens than in biopsy specimens.
CONCLUSION: This population-based study confirms previous studies and highlights potential determinants of acquired T790M mutation to be considered in clinical practice. Copyright
© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Acquired EGFR T790M gene mutation; EGFR-TKI; epidermal growth factor; population-based study; receptor-tyrosine kinase inhibitor

Mesh:

Substances:

Year:  2018        PMID: 29715155     DOI: 10.21873/anticanres.12577

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  8 in total

1.  Comparison of T790M Acquisition After Treatment With First- and Second-Generation Tyrosine-Kinase Inhibitors: A Systematic Review and Network Meta-Analysis.

Authors:  Po-Chun Hsieh; Yao-Kuang Wu; Chun-Yao Huang; Mei-Chen Yang; Chan-Yen Kuo; I-Shiang Tzeng; Chou-Chin Lan
Journal:  Front Oncol       Date:  2022-06-28       Impact factor: 5.738

2.  Association Of Initial Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment And EGFR Exon 19 Deletion With Frequency Of The T790M Mutation In Non-Small Cell Lung Cancer Patients After Resistance To First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.

Authors:  Wen Gao; Jing He; Shi-Dai Jin; Jing Xu; Tong-Fu Yu; Wei Wang; Quan Zhu; Hui Dai; Hao Wu; Yi-Qian Liu; Yong-Qian Shu; Ren-Hua Guo
Journal:  Onco Targets Ther       Date:  2019-11-08       Impact factor: 4.147

3.  Comparison of T790M Acquisition Between Patients Treated with Afatinib and Gefitinib as First-Line Therapy: Retrospective Propensity Score Matching Analysis.

Authors:  Byung Woo Yoon; Jae Hoon Kim; Seung Hyeon Lee; Chang-Min Choi; Jin Kyung Rho; Shinkyo Yoon; Dae Ho Lee; Sang-We Kim; Tae-Won Jang; Jae Cheol Lee
Journal:  Transl Oncol       Date:  2019-04-25       Impact factor: 4.243

4.  The Impact of Acquired EGFR T790M Mutation and EGFR Circulating Cell-Free DNA on Survival in Patients with Lung Adenocarcinoma Following EGFR-TKI Therapy.

Authors:  Wen-Chien Cheng; Te-Chun Hsia; Chih-Yen Tu; Hung-Jen Chen
Journal:  Onco Targets Ther       Date:  2021-01-05       Impact factor: 4.147

5.  Clinical impact of rebiopsy among patients with epidermal growth factor receptor-mutant lung adenocarcinoma in a real-world clinical setting.

Authors:  Yunha Nam; Ho Cheol Kim; Young-Chul Kim; Seung Hun Jang; Kye Young Lee; Shin Yup Lee; Sang Hoon Lee; Sung Yong Lee; Seong Hoon Yoon; Jeong-Seon Ryu; Tae Won Jang; Yoon Soo Chang; Seung Joon Kim; Chan Kwon Park; Jeong Eun Lee; Chi Young Jung; Chang-Min Choi
Journal:  Thorac Cancer       Date:  2021-02-02       Impact factor: 3.500

Review 6.  Advances in targeting acquired resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors.

Authors:  Justin A Chen; Jonathan W Riess
Journal:  J Thorac Dis       Date:  2020-05       Impact factor: 3.005

7.  The Value of Next-Generation Sequencing for Treatment in Non-Small Cell Lung Cancer Patients: The Observational, Real-World Evidence in China.

Authors:  Yan Zhang; Wen-Xiang Shen; Li-Na Zhou; Min Tang; Yue Tan; Chun-Xia Feng; Ping Li; Li-Qiang Wang; Min-Bin Chen
Journal:  Biomed Res Int       Date:  2020-01-24       Impact factor: 3.411

8.  The impact of EGFR exon 19 deletion subtypes on clinical outcomes in non-small cell lung cancer.

Authors:  Chao Zhao; Tao Jiang; Jiayu Li; Yan Wang; Chunxia Su; Xiaoxia Chen; Shengxiang Ren; Xuefei Li; Caicun Zhou
Journal:  Transl Lung Cancer Res       Date:  2020-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.